We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Superior Single-Cell Library Preparation Technology Now Available for Additional Platforms

By LabMedica International staff writers
Posted on 17 Feb 2014
Innovative single-cell DNA library preparation kits can now be used with Illumina sequencing platforms.

Rubicon Genomics (Ann Arbor, MI, USA) now offers its PicoPLEX DNA-seq kits for use with Illumina next-generation sequencing (NGS) platforms. More...
The kits are among Rubicon’s sample-specific library preparation products used in clinical and research testing on NGS, microarray, and quantitative polymerase chain reaction (qPCR) platforms. PicoPLEX’s excellent robustness and reproducibility offer excellent single-cell DNA amplification for microarray and PCR-based preimplantation genetic screening and diagnosis. PicoPLEX DNA-seq now enables clinicians and researchers to access PicoPLEX technology for analyses conducted on Illumina NGS systems.

PicoPLEX DNA-seq kits amplify DNA to yield a highly reproducible NGS-ready library from a single cell with input concentrations of six picograms or less. PicoPLEX DNA-seq employs the same technology currently used by in vitro fertilization (IVF) clinics to detect chromosomal aneuploidies, copy number variations, and single-gene disorders in reproductive cells. It is also used for the genetic characterization of other single-cell samples such as circulating tumor cells. The easy-to-use, three-step process is performed in a single tube or well in less than 3 hours, thereby reducing error and contamination, speeding time to results, and reducing costs.

James Koziarz, PhD, CEO of Rubicon Genomics, commented, “PicoPLEX DNA-seq emphasizes our commitment to increasing the robustness and reproducibility of DNA analyses while also delivering greater speed, efficiency and cost savings. This launch represents another milestone in our ongoing strategy to make Rubicon Genomics’ proprietary library preparation technology available to users of all sequencing platforms.”

Dr. Brian Mariani, chief scientist and scientific director of the Genetics and IVF Institute, helped test the PicoPLEX DNA-seq kits. He commented, “Remarkably, the sequencing data from the PicoPLEX DNA-seq libraries of embryo DNA clearly identified a male balanced translocation that had not been detected by previous microarray and FISH [fluorescence in-situ hybridization] analyses. This is a significant example of how PicoPLEX sequencing data can expose important structural rearrangements missed by other approaches.”

At the 15th annual Advances in Genome Biology and Technology meeting (AGBT 2014; February 12–15, 2014, Marco Island, FL, USA), Rubicon CSO Dr. John Langmore presented studies highlighting PicoPLEX DNA-seq and discussed “Preimplantation genetic screening and diagnostics (PGS/PGD) at low NGS coverage for aneuploidy, CNV, and single-gene disorder detection for in vitro fertilization.”

Related Links:

Rubicon Genomics
PicoPLEX DNA-seq
Advances in Genome Biology and Technology Meeting



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Thyroid Test
Anti-Thyroid EIA Test
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.